RNA– tag –
-
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 6 Final: BRD4 and CDK Crosstalk — The Future of Super-Enhancer Targeting)
From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. In this final installment, we turn to BRD4, a pivotal co-regulator that interacts closely with CDKs and controls super-enhancer–driv... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 5: CDK11 — Pause-Checkpoint and Emerging Therapeutic Potential)
In Part 4, we examined CDK12/13 and their role in DNA repair and synthetic lethality. Here in Part 5, we focus on CDK11, a kinase that has recently gained attention for its role as a pause-checkpoint regulator in transcription, preceding... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 4: CDK12 & CDK13 — DNA Repair and Synthetic Lethality Strategies)
In Parts 1–3, we reviewed CDK7/8 and CDK9. Here in Part 4, we turn to CDK12 and CDK13, transcriptional kinases that stabilize elongation of long DNA repair genes. They serve as “guardians” of genome stability and represent key players in... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 3: CDK9 — The Bottleneck of Transcription Elongation and Clinical Development)
In Parts 1 and 2, we introduced CDK7 and CDK8 in transcription initiation. Here in Part 3, we focus on CDK9, the central kinase controlling the transition from paused RNA polymerase II (Pol II) to productive elongation. Among transcripti... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 2: CDK7 & CDK8 — Gatekeepers of Transcription Initiation and Emerging Therapeutics)
In Part 1, we reviewed the fundamentals of transcription and the CDK family. In this article, we focus on CDK7 and CDK8, two kinases that act at the transcriptional “starting line.” While both regulate initiation, their roles and drug di... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 1: Introduction — Overview of Transcription and CDK Families)
This series will explore the latest drug discovery trends targeting the transcriptional machinery. In Part 1, we provide an introduction: what transcription is, how CDKs regulate it, and why transcriptional CDKs are emerging as hot targe... -
Series “Reading 2025 Layoffs”: Reshaping by Disease Areas: From Oncology to Neuroscience (Part 2)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 2 Key Takeaways Oncology leads the reallocation: Cell therapies and solid tumors force a focus on indication picking, manufacturability, and reimbursement realism... -
Can RNA Become a Drug Target? ― Insights from Science and Biotech Frontlines
In recent years, the question of whether RNA can serve as a viable therapeutic target has become one of the most exciting debates in life sciences and drug discovery. Traditionally, drug development has focused on proteins as the primary...
1